Atezolizumab (Tecentriq®)

Assessment Status NCPE Assessment Process Complete
Drug Atezolizumab
Brand Tecentriq®
Indication As monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK‑positive tumour mutations should also have received targeted therapy before receiving atezolizumab.
Assessment Process
Rapid review commissioned 08/08/2017
Rapid review completed 09/10/2017
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full pharmacoeconomic assessment commissioned by HSE 11/10/2017
Pre-submission consultation with Applicant 28/11/2017
Full submission received from Applicant 08/01/2018
Preliminary review sent to Applicant 29/05/2018
NCPE assessment re-commenced 15/06/2018
Follow-up to preliminary review sent to Applicant 31/07/2018
NCPE assessment re-commenced 21/08/2018
Factual accuracy sent to Applicant 04/09/2018
NCPE assessment re-commenced 19/09/2018
NCPE assessment completed 20/09/2018
NCPE assessment outcome The NCPE recommends that atezolizumab not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments.

Technical Summary

This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations, March 2019.